Ladeering (Ethinylestradiol, Etonogestrel)

Ladeering, a combined hormonal contraceptive, is indicated for conditions related to reproductive hormone regulation.

• Contraception: prevents unintended pregnancy in women of childbearing potential.
• Menstrual cycle regulation: helps establish a predictable monthly bleeding pattern.
• Dysmenorrhea relief: reduces painful menstrual cramps associated with ovulatory cycles.

• Ethinylestradiol and etonogestrel act synergistically to suppress the hypothalamic‑pituitary‑ovarian axis, inhibiting the mid‑cycle surge of luteinizing hormone and follicle‑stimulating hormone, thereby preventing ovulation. The estrogen component stabilizes the endometrial lining, while the progestogen thickens cervical mucus and alters endometrial receptivity, reducing the likelihood of implantation.

Ladeering may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Headache: tension‑type or migraine‑like pain.
• Breast tenderness: temporary swelling or discomfort.
• Vaginal irritation: local discomfort or discharge.
• Mood changes: irritability or emotional fluctuations.
• Weight gain: modest increase in body weight.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
• Stroke: cerebrovascular accident, especially in high‑risk individuals.
• Hepatic adenoma: benign liver tumor.
• Hypertension: new‑onset or worsening high blood pressure.
• Allergic reaction: rash, itching, swelling, or anaphylaxis.

Before prescribing Ladeering, clinicians should assess patient risk factors and contraindications.

• Smoking status: avoid in women over 35 who smoke due to increased thrombotic risk.
• Cardiovascular disease: contraindicated in patients with history of myocardial infarction or stroke.
• Liver disease: use with caution in severe hepatic impairment.
• Migraine with aura: avoid because of elevated stroke risk.
• Breast cancer history: contraindicated in current or past estrogen‑dependent malignancies.
• Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Ladeering can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): may reduce anticoagulant effect, increasing clot risk.
• Antiepileptics (e.g., carbamazepine, phenytoin): can lower hormone levels, reducing contraceptive effectiveness.
• Rifampin and other enzyme inducers: markedly decrease plasma concentrations of both hormones.

Moderate Interactions (Monitor Closely)

• Antifungals (e.g., ketoconazole): may increase hormone levels, raising side‑effect risk.
• St. John’s Wort: may modestly reduce contraceptive efficacy.
• Protease inhibitors: can affect hormone metabolism, requiring clinical monitoring.